Google
BCAX — BICARA THERAPEUTICS INC. COMMON STOCK (Healthcare >> Biotechnology)
BCAX FAQ
What is BCAX's ROE?
BICARA THERAPEUTICS INC. COMMON STOCK reports a Return on Equity (ROE) of -30.61%.
What is BCAX's dividend yield?
BICARA THERAPEUTICS INC. COMMON STOCK offers a dividend yield of 0.00%.
What is BCAX's Deepscope Quality Score?
Deepscope rates BCAX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BCAX?
Deepscope's AI Timing Score for BCAX is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BCAX belong to?
BICARA THERAPEUTICS INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 20.00
Price
-0.41
(-2.01%)
Day Change
|
|
|---|
BCAX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 20.00 |
| PBV / Sector |
2.56 / 4.63
|
| Earning Per Share | -2.39 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
11.45 M
GREAT
|
| Average 1W Daily Value |
10.33 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:27 |
| Symbol | BCAX |
| Name | BICARA THERAPEUTICS INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 65.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,314.08 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 116 Huntington Avenue, Boston, MA, United States, 02116
Phone: 617 468 4219
Website: https://www.bicara.com
Employees: 103
Sector: Healthcare >> Biotechnology
Description: Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
